Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BCMA-targeting therapy

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

- PMLiVE

EMA approves GSK’s triple COPD therapy

Trelegy can now be marketed as a maintenance treatment in Europe

- PMLiVE

Ex-GSK head Witty to head group overseeing UK fast-track scheme

Medicines selected for the AAP could be made available much earlier

- PMLiVE

GSK to replace R&D head Vallance with Calico’s Hal Barron

Barron will also hold an executive director position on GSK’s board

- PMLiVE

GSK’s R&D head Vallance departs, possibly for government role

An independent panel of scientists proposed the UK role to Vallance, according to the FT

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

National Institute for Health and Care Excellence NICE logo

NICE backs GSK’s ‘bubble baby’ gene therapy

Strimvelis will treat children under the NHS for immunodeficiency

- PMLiVE

GSK’s shingles vaccine Shingrix claims US approval

Becomes first alternative to Merck & Co’s Zostavax

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

- PMLiVE

Former GSK CEO joins Synthego’s advisory board

Sir Andrew Witty will expand the team’s bioinformatics expertise

- PMLiVE

With US approval, GSK now needs rapid uptake for COPD triple

Aims to quickly launch the predicted blockbuster to revive its R&D portfolio

- PMLiVE

GSK’s Shingrix sails through FDA advisory committee

Shingles vaccine data proved safe and effective, says the panel

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links